Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 3Terminated 2Unknown 1Recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Head & Neck 1Gynecologic 1Genitourinary 1

Conditions

Melanoma 10Carcinoma, Non-Small-Cell Lung 9Carcinoma, Renal Cell 8Triple Negative Breast Neoplasms 5Neoplasm Metastasis 5Squamous Cell Carcinoma of Head and Neck 4Pancreatic Neoplasms 4Colorectal Neoplasms 4Stomach Neoplasms 3Ovarian Neoplasms 3Neoplasms 2Lymphoma 2Head and Neck Neoplasms 2Glioblastoma 2Gastrointestinal Stromal Tumors 2Esophageal Squamous Cell Carcinoma 2Esophageal Neoplasms 2von Hippel-Lindau Disease 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Spinocerebellar Degenerations 1Solid Tumors 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Rectal Neoplasms 1Prostatic Neoplasms 1Pheochromocytoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1

Interventions

Fluorouracil 17Cisplatin 17pembrolizumab 12Radiotherapy 11Oxaliplatin 10Irinotecan 9Paclitaxel 6Leucovorin 6Docetaxel 6Carboplatin 6Capecitabine 6Neoadjuvant Therapy 5Trastuzumab 4Panitumumab 4Gefitinib 4Esophagectomy 4Cyclophosphamide 4Cetuximab 4Surgical Procedures, Operative 3Celecoxib 3tegafur-gimeracil-oteracil 2spartalizumab 2sodium glycididazole 2niraparib 2fludarabine 2S 1 (combination) 2Plicamycin 2Pemetrexed 2Lapatinib 2Gemcitabine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Esophageal Neoplasms × spartalizumab × Clear all
NCT04152018 2025-05-28

Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.

Pfizer

Phase 1 Terminated
85 enrolled
GastrointestinalGenitourinaryGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Bile Duct Neoplasms, Carcinoma, Renal Cell, Esophageal Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Endometrial Neoplasms

NCT04171141 2025-01-16

Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestinal Tumors.

Pfizer

Phase 1 Terminated
79 enrolled 42 charts
Gastrointestinal

Digestive System Neoplasms, Esophageal Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡